The properties use and production process of urokinase Drug interaction
There is no report on the interaction between urokinase and other drugs. Since
this product is a thrombolytic drug, drugs that affect platelet function, such
as aspirin, indomethacin, phenylbutazone, etc., should not be used in
combination. Heparin and oral anticoagulants should not be used together with
large doses of this product to avoid the increased risk of bleeding. Adverse
reactions The toxicity of urokinase is very low, and the median lethal dose of
intravenous injection in mice is greater than 1 million international units/kg
body weight. There is also no obvious antigenicity, teratogenicity,
carcinogenicity, or mutagenicity. There are rare reports of allergic reactions
in clinical applications.
However, since this product increases plasmin activity
and reduces circulating unconjugated plasminogen and fibrin-bound plasminogen, a
serious risk of bleeding may occur. The adverse reaction of urokinase is also
less than that of streptokinase. There are mainly various bleeding, and
occasionally allergic reactions such as rash and urticaria, as well as
gastrointestinal reactions such as fever, headache, nausea, vomiting, and loss
of appetite. Little to no antigenic response. Pharmacological action and
mechanism of action Urokinase directly acts on the endogenous fibrinolytic
system and can catalyze the cleavage of plasminogen into plasmin, which can not
only degrade fibrin clots but also degrade fibrinogen, Coagulation factor V and
coagulation factor VIII, etc., thereby exerting a thrombolytic effect. This
product has a quick onset and good effect on newly formed thrombus. This product
can also increase the activity of vascular ADP enzymes, inhibit ADP-induced
platelet aggregation, and prevent thrombosis. After intravenous infusion of this
product, the activity of plasmin in the patient's body was significantly
increased; after a few hours of drug withdrawal, the activity of plasmin
returned to the original level. However, reductions in plasma fibrin or
fibrinogen levels, and increases in their degradation products, can last for 12
to 24 hours. This product shows that the thrombolytic effect is significantly
correlated with the drug dose and the time of administration.
The above is the relevant content summarized by the editor of Kangyuan
Company. If you want to know more, please continue to pay attention to us. We
will regularly update you about Human chorionic gonadotropin, Human Menopausal
Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, and Hormone
API Manufacturer Related content, hope to help you.